FOXO4-DRI vs Livagen
Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
FOXO4-DRI
Senolytic peptide
Livagen
Khavinson liver bioregulator
About FOXO4-DRI
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, studied for selective clearance of senescent cells.
About Livagen
Livagen is a Khavinson tetrapeptide bioregulator (Lys-Glu-Asp-Ala / KEDA) originally isolated from liver tissue extracts in Russian gerontology research. It has been studied in animal and cell-culture models for hepatocyte function, chromatin decondensation in lymphocytes, and liver-related ageing parameters, alongside other organ-targeted Khavinson peptides such as Pancragen and Cortagen. Sold by research-peptide vendors at 5–20 mg vial sizes for laboratory work; not approved by FDA, MHRA, Health Canada, or TGA for human use. Research-use only — Pepticker does not provide medical advice and this entry summarises published preclinical research, not a dosing protocol.